Comprehensive Stock Comparison
Compare Can-Fite BioPharma Ltd. (CANF) vs argenx SE (ARGX) vs Akari Therapeutics, Plc (AKTX) vs Abivax S.A. (ABVX) vs RAPT Therapeutics, Inc. (RAPT) Stock
Analyze side-by-side fundamentals, valuation, growth, and profitability to decide which stock is the better buy.
Selected Stocks
Add up to 10 tickers. Use presets or search to get started.
Quick Verdict
| Category | Winner | Why |
|---|---|---|
| Growth | ABVX | 133.5% revenue growth vs CANF's -9.3% |
| Quality / Margins | ARGX | 23.3% net margin vs ABVX's -21.9% |
| Stability / Safety | CANF | Beta 0.36 vs ABVX's 1.07, lower leverage |
| Dividends | Tie | Neither pays a meaningful dividend |
| Momentum (1Y) | ABVX | +14.8% vs AKTX's -72.9% |
| Efficiency (ROA) | ARGX | 12.9% ROA vs ABVX's -277.5% |
Who Each Stock Is For
Income & stability
Growth exposure
Long-term compounding (10Y)
Sleep-well-at-night portfolio
Defensive / Recession hedge
Business Model
What each company does and how it makes money
Can-Fite BioPharma is a clinical-stage biopharmaceutical company developing small molecule drugs targeting inflammatory diseases and cancer. It generates revenue primarily through licensing agreements and milestone payments from partners — with no commercial products yet — as it advances its lead candidates through clinical trials. The company's competitive advantage lies in its proprietary A3 adenosine receptor platform, which targets a novel pathway for treating autoimmune and inflammatory conditions.
argenx is a biotechnology company that develops antibody-based therapies for autoimmune diseases. It generates nearly all its revenue from VYVGART — its FcRn blocker for conditions like myasthenia gravis — with additional income from partnerships and licensing. The company's key advantage is its proprietary antibody engineering platform that creates differentiated therapies with potentially better safety and efficacy profiles.
Akari Therapeutics is a clinical-stage biopharmaceutical company developing advanced therapies for autoimmune and inflammatory diseases. It generates no revenue currently — its business model depends on advancing its lead candidate nomacopan through clinical trials to eventually secure regulatory approvals and commercialization partnerships. The company's key advantage lies in nomacopan's dual mechanism of action targeting both complement and leukotriene pathways — a differentiated approach that could offer superior efficacy in treating complex inflammatory conditions.
Abivax is a clinical-stage biotechnology company developing novel therapies for inflammatory diseases, infectious diseases, and cancer. It generates revenue primarily through research grants and partnerships while advancing its lead candidate ABX464 through clinical trials for ulcerative colitis, Crohn's disease, and other inflammatory conditions. The company's competitive advantage lies in its proprietary small molecule platform technology that targets RNA biology to modulate inflammation and viral replication.
RAPT Therapeutics is a clinical-stage biopharmaceutical company developing oral small molecule therapies for cancer and inflammatory diseases. It generates no revenue yet as it's in clinical trials, with future income dependent on potential drug approvals and commercialization. The company's competitive advantage lies in its targeted CCR4 antagonist platform that selectively inhibits immune cell migration to diseased tissues.
Financial Metrics Comparison
Side-by-side fundamentals across 5 stocks. BestLagging
Financial Scorecard
ARGX leads in 2 of 6 categories (Financial Metrics, Profitability & Efficiency). ABVX leads in 1 (Total Returns). 2 tied.
Financial Metrics (TTM)
ARGX and RAPT operate at a comparable scale, with $4.0B and $0 in trailing revenue. ARGX is the more profitable business, keeping 23.3% of every revenue dollar as net income compared to ABVX's -21.9%. On growth, ARGX holds the edge at +5.1% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | CANFCan-Fite BioPharm… | ARGXargenx SE | AKTXAkari Therapeutic… | ABVXAbivax S.A. | RAPTRAPT Therapeutics… |
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $560,000 | $4.0B | $0 | $15M | $0 |
| EBITDAEarnings before interest/tax | -$9M | $95M | -$17M | -$358M | -$112M |
| Net IncomeAfter-tax profit | -$9M | $923M | -$16M | -$332M | -$106M |
| Free Cash FlowCash after capex | -$8M | $213M | -$10M | -$250M | -$87M |
| Gross MarginGross profit ÷ Revenue | +100.0% | +75.5% | — | +100.0% | — |
| Operating MarginEBIT ÷ Revenue | -16.0% | -1.0% | — | -23.7% | — |
| Net MarginNet income ÷ Revenue | -15.7% | +23.3% | — | -21.9% | — |
| FCF MarginFCF ÷ Revenue | -14.9% | +5.4% | — | -16.5% | — |
| Rev. Growth (YoY)Latest quarter vs prior year | -36.1% | +5.1% | — | -40.6% | — |
| EPS Growth (YoY)Latest quarter vs prior year | +36.4% | +12.6% | -80.2% | -144.6% | +82.9% |
Valuation Metrics
| Metric | CANFCan-Fite BioPharm… | ARGXargenx SE | AKTXAkari Therapeutic… | ABVXAbivax S.A. | RAPTRAPT Therapeutics… |
|---|---|---|---|---|---|
| Market CapShares × price | $14.2B | $47.5B | $12.6B | $9.6B | $7.7B |
| Enterprise ValueMkt cap + debt − cash | $14.2B | $46.0B | $12.6B | $9.5B | $7.5B |
| Trailing P/EPrice ÷ TTM EPS | -4.40x | 60.01x | -0.00x | -36.72x | -2.27x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 25.57x | — | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | — | — |
| EV / EBITDAEnterprise value multiple | — | — | — | — | — |
| Price / SalesMarket cap ÷ Revenue | 9999.00x | 21.67x | — | 753.36x | — |
| Price / BookPrice ÷ Book value/share | 6.34x | 9.09x | 0.00x | 159.73x | 1.56x |
| Price / FCFMarket cap ÷ FCF | — | — | — | — | — |
Profitability & Efficiency
ARGX delivers a 15.1% return on equity — every $100 of shareholder capital generates $15 in annual profit, vs $-2 for CANF. ARGX carries lower financial leverage with a 0.01x debt-to-equity ratio, signaling a more conservative balance sheet compared to ABVX's 2.40x. On the Piotroski fundamental quality scale (0–9), ABVX scores 4/9 vs CANF's 1/9, reflecting mixed financial health.
| Metric | CANFCan-Fite BioPharm… | ARGXargenx SE | AKTXAkari Therapeutic… | ABVXAbivax S.A. | RAPTRAPT Therapeutics… |
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | -2.1% | +15.1% | -69.4% | -149.0% | -69.5% |
| ROA (TTM)Return on assets | -114.0% | +12.9% | -34.7% | -2.8% | -63.7% |
| ROICReturn on invested capital | -4.5% | -0.5% | -172.5% | — | -155.7% |
| ROCEReturn on capital employed | -108.1% | -0.4% | -142.3% | -98.5% | -79.3% |
| Piotroski ScoreFundamental quality 0–9 | 1 | 3 | 3 | 4 | 2 |
| Debt / EquityFinancial leverage | 0.02x | 0.01x | 0.15x | 2.40x | 0.02x |
| Net DebtTotal debt minus cash | -$5M | -$1.5B | $661,000 | -$47M | -$165M |
| Cash & Equiv.Liquid assets | $5M | $1.5B | $3M | $144M | $170M |
| Total DebtShort + long-term debt | $104,000 | $39M | $3M | $97M | $4M |
| Interest CoverageEBIT ÷ Interest expense | -580.71x | 166.64x | -47.14x | -21.56x | — |
Total Returns (with DRIP)
A $10,000 investment in ABVX five years ago would be worth $146,121 today (with dividends reinvested), compared to $35 for AKTX. Over the past 12 months, ABVX leads with a +1479.2% total return vs AKTX's -72.9%. The 3-year compound annual growth rate (CAGR) favors ABVX at 144.5% vs AKTX's -67.5% — a key indicator of consistent wealth creation.
| Metric | CANFCan-Fite BioPharm… | ARGXargenx SE | AKTXAkari Therapeutic… | ABVXAbivax S.A. | RAPTRAPT Therapeutics… |
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | +2059.1% | -8.7% | -18.6% | -9.3% | +82.0% |
| 1-Year ReturnPast 12 months | +169.9% | +22.8% | -72.9% | +1479.2% | +535.7% |
| 3-Year ReturnCumulative with dividends | +75.3% | +109.5% | -96.6% | +1361.2% | -75.4% |
| 5-Year ReturnCumulative with dividends | -76.5% | +125.2% | -99.6% | +1361.2% | -61.3% |
| 10-Year ReturnCumulative with dividends | -98.5% | +3234.4% | -99.9% | +1361.2% | -44.3% |
| CAGR (3Y)Annualised 3-year return | +20.6% | +28.0% | -67.5% | +144.5% | -37.3% |
Risk & Volatility
CANF is the less volatile stock with a 0.36 beta — it tends to amplify market swings less than ABVX's 1.07 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. RAPT currently trades 100.0% from its 52-week high vs AKTX's 13.7% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | CANFCan-Fite BioPharm… | ARGXargenx SE | AKTXAkari Therapeutic… | ABVXAbivax S.A. | RAPTRAPT Therapeutics… |
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.36x | 0.44x | 0.63x | 1.07x | 0.78x |
| 52-Week HighHighest price in past year | $4.93 | $934.62 | $1.73 | $148.83 | $57.99 |
| 52-Week LowLowest price in past year | $0.17 | $510.06 | $0.22 | $4.77 | $5.67 |
| % of 52W HighCurrent price vs 52-week peak | +96.3% | +82.1% | +13.7% | +81.5% | +100.0% |
| RSI (14)Momentum oscillator 0–100 | 68.6 | 33.9 | 52.2 | 45.5 | 79.2 |
| Avg Volume (50D)Average daily shares traded | 4.3M | 301K | 387K | 1.2M | 2.8M |
Analyst Outlook
Analyst consensus: CANF as "Buy", ARGX as "Buy", AKTX as "Buy", ABVX as "Buy", RAPT as "Hold". Consensus price targets imply 12601.1% upside for AKTX (target: $30) vs 3.5% for RAPT (target: $60).
| Metric | CANFCan-Fite BioPharm… | ARGXargenx SE | AKTXAkari Therapeutic… | ABVXAbivax S.A. | RAPTRAPT Therapeutics… |
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy | Buy | Buy | Hold |
| Price TargetConsensus 12-month target | $7.25 | $1026.71 | $30.00 | $142.50 | $60.00 |
| # AnalystsCovering analysts | 4 | 35 | 7 | 8 | 15 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | — | — |
| Dividend StreakConsecutive years of raises | — | — | — | — | — |
| Dividend / ShareAnnual DPS | — | — | — | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Historical Charts
Charts are rendered on first load. Hover for details.
Chart 1Total Return — 5 Years (Rebased to 100)
| Stock | Nov 23 | Feb 26 | Change |
|---|---|---|---|
| Can-Fite BioPharma … (CANF) | 100 | 193.9 | +93.9% |
| argenx SE (ARGX) | 100 | 168.9 | +68.9% |
| Akari Therapeutics,… (AKTX) | 100 | 6.6 | -93.4% |
| Abivax S.A. (ABVX) | 117.59 | 1,342.89 | +1042.0% |
| RAPT Therapeutics, … (RAPT) | 100 | 50.67 | -49.3% |
Abivax S.A. (ABVX) returned +1.4K% over 5 years vs Akari Therapeutics,… (AKTX)'s -100%. A $10,000 investment in ABVX 5 years ago would be worth $146,121 today (including dividends reinvested).
Chart 2Revenue Growth — 10 Years
| Stock | 2015 | 2024 | Change |
|---|---|---|---|
| Can-Fite BioPharma … (CANF) | $164717.00 | $674000.00 | +309.2% |
| argenx SE (ARGX) | $7M | $2.2B | +29130.4% |
| Akari Therapeutics,… (AKTX) | $0.00 | $0.00 | — |
| Abivax S.A. (ABVX) | $42000.00 | $11M | +25595.2% |
| RAPT Therapeutics, … (RAPT) | $0.00 | $0.00 | — |
Can-Fite BioPharma Ltd.'s revenue grew from $0M (2015) to $1M (2024) — a 16.9% CAGR. argenx SE's revenue grew from $7M (2015) to $2.2B (2024) — a 87.9% CAGR.
Chart 3Net Margin Trend — 10 Years
| Stock | 2015 | 2024 | Change |
|---|---|---|---|
| Can-Fite BioPharma … (CANF) | -29.1% | -11.7% | +59.9% |
| argenx SE (ARGX) | -2.2% | 38.0% | +1802.4% |
| Abivax S.A. (ABVX) | -379.9% | -16.3% | +95.7% |
| RAPT Therapeutics, … (RAPT) | -10.5% | -54.9% | -423.4% |
Can-Fite BioPharma Ltd.'s net margin went from -29% (2015) to -12% (2024). argenx SE's net margin went from -2% (2015) to 38% (2024).
Chart 4EPS Growth — 10 Years
| Stock | 2015 | 2024 | Change |
|---|---|---|---|
| Can-Fite BioPharma … (CANF) | -81 | -1.08 | +98.7% |
| argenx SE (ARGX) | -1.06 | 12.78 | +1305.7% |
| Akari Therapeutics,… (AKTX) | -10,640 | -1,660 | +84.4% |
| Abivax S.A. (ABVX) | -1.64 | -2.8 | -70.7% |
| RAPT Therapeutics, … (RAPT) | -10.95 | -25.49 | -132.9% |
Can-Fite BioPharma Ltd.'s EPS grew from $-81.00 (2015) to $-1.08 (2024). argenx SE's EPS grew from $-1.06 (2015) to $12.78 (2024).
Chart 5Free Cash Flow — 5 Years
Can-Fite BioPharma Ltd. generated $-8M FCF in 2024 (+23% vs 2021). argenx SE generated $-151M FCF in 2024 (+79% vs 2021).
CANF vs ARGX vs AKTX vs ABVX vs RAPT: Key Questions Answered
8 questions · data-driven answers · updated daily
01Is CANF or ARGX or AKTX or ABVX or RAPT a better buy right now?
argenx SE (ARGX) offers the better valuation at 60.0x trailing P/E (25.6x forward), making it the more compelling value choice. Analysts rate Can-Fite BioPharma Ltd. (CANF) a "Buy" — based on 4 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — CANF or ARGX or AKTX or ABVX or RAPT?
Over the past 5 years, Abivax S.A. (ABVX) delivered a total return of +1361%, compared to -99.6% for Akari Therapeutics, Plc (AKTX). A $10,000 investment in ABVX five years ago would be worth approximately $146K today (assuming dividends reinvested). Over 10 years, the gap is even starker: ARGX returned +32.3% versus AKTX's -99.9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — CANF or ARGX or AKTX or ABVX or RAPT?
By beta (market sensitivity over 5 years), Can-Fite BioPharma Ltd. (CANF) is the lower-risk stock at 0.36β versus Abivax S.A.'s 1.07β — meaning ABVX is approximately 196% more volatile than CANF relative to the S&P 500. On balance sheet safety, argenx SE (ARGX) carries a lower debt/equity ratio of 1% versus 2% for Abivax S.A. — giving it more financial flexibility in a downturn.
04Which has better profit margins — CANF or ARGX or AKTX or ABVX or RAPT?
argenx SE (ARGX) is the more profitable company, earning 38.0% net margin versus -1633.1% for Abivax S.A. — meaning it keeps 38.0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: AKTX leads at 0.0% versus -1602.9% for ABVX. At the gross margin level — before operating expenses — CANF leads at 100.0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
05Is CANF or ARGX or AKTX or ABVX or RAPT more undervalued right now?
Analyst consensus price targets imply the most upside for AKTX: 12601.1% to $30.00.
06Which pays a better dividend — CANF or ARGX or AKTX or ABVX or RAPT?
None of the stocks in this comparison currently pay a material dividend. All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is CANF or ARGX or AKTX or ABVX or RAPT better for a retirement portfolio?
For long-horizon retirement investors, Abivax S.A. (ABVX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1.07), +1361% 10Y return). Both have compounded well over 10 years (ABVX: +1361%, RAPT: -44.3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between CANF and ARGX and AKTX and ABVX and RAPT?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that beat both.